DDInter624 DDInter1289
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Carbamazepine
Carbamazepine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nicotinamide
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nicotinamide
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nicotinamide
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Nicotinamide
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2B6 Inducers
Cytochrome P450 2B6 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Carbamazepine
Carbamazepine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nicotinamide
Efavirenz {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nicotinamide
Efavirenz {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nicotinamide
Efavirenz {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nicotinamide
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nicotinamide
Efavirenz {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nicotinamide
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Carbamazepine (Compound) and Carbamazepine may cause a minor interaction that can limit clinical effects when taken with Nicotinamide
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Nicotinamide
Efavirenz (Compound) is included by Cytochrome P450 2B6 Inducers (Pharmacologic Class) and Cytochrome P450 2B6 Inducers (Pharmacologic Class) includes Carbamazepine (Compound) and Carbamazepine may cause a minor interaction that can limit clinical effects when taken with Nicotinamide
Efavirenz (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may cause a minor interaction that can limit clinical effects when taken with Nicotinamide
Efavirenz (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide
Efavirenz (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Canagliflozin (Compound) and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Nicotinamide
Efavirenz (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Nicotinamide